---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-115027"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:32:19.023764+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Replimune Q2 FY2024 net loss $60M; cash $496.8M; RP1 data and new CFO announced

## Summary
- Net loss of $60.0M for Q2 ended Sep 30, 2023, compared to $43.1M loss a year ago.
- Cash, equivalents & short-term investments $496.8M as of Sep 30, 2023; funds operations into H2 2025.
- R&D expenses $49.1M (up from $28.8M) driven by clinical and manufacturing costs for lead programs.
- Appointed Emily Hill as CFO; she was previously CFO of PTC Therapeutics.
- Topline CERPASS trial data and initial IGNYTE melanoma snapshot expected in early December 2023.

## SEC filing metadata
- accession: 0001104659-23-115027
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465923115027/0001104659-23-115027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465923115027/tm2330041d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-115027
- JSON: https://secwatch.observer/filing/0001104659-23-115027.json
- Plain text: https://secwatch.observer/filing/0001104659-23-115027.txt

## Key facts
- Earnings Releases
  Replimune Group, Inc. reported financial results for fiscal second quarter ended September 30, 2023.
  - Period: fiscal second quarter ended September 30, 2023
  - Result: reported results
  source text: Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2023 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737953/000110465923115027/0001104659-23-115027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.